A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo Controlled Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of Induction Therapy With RPC1063 in Patients With Moderately to Severely Active Ulcerative Colitis

Trial Profile

A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo Controlled Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of Induction Therapy With RPC1063 in Patients With Moderately to Severely Active Ulcerative Colitis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Ozanimod (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms TOUCHSTONE
  • Sponsors Celgene International SARL
  • Most Recent Events

    • 16 Oct 2017 According to a Celgene Corporation media release, data from the open-label extension will be presented at the World Congress of Gastroenterology at ACG2017.
    • 16 Oct 2017 Results (data cut-off of March 2017) presented in a Celgene Corporation Media Release.
    • 19 Oct 2016 Results from extension part of this trial presented at the 24th United European Gastroenterology Week.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top